Drugs /

abc294640

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, ABC294640 competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.

Clinical Trials

View Clinical Trials for abc294640

Abc294640 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating abc294640, 2 are phase 2 (2 open).

Cholangiocarcinoma and prostate adenocarcinoma are the most common diseases being investigated in abc294640 clinical trials [2].

Drug Details

Synonyms [2]:
opaganib, sphingosine kinase-2 inhibitor abc294640, sphingosine kinase-2 inhibitor abc294640, sk2 inhibitor abc294640, 4-pyridinylmethyl-3-(4-chlorophenyl) adamantane carboxamide, 4-pyridinylmethyl-3-(4-chlorophenyl) adamantane carboxamide, yeliva, abc-294640, abc 294640, tricyclo(3.3.1.13,7)decane-1-carboxamide, 3-(4-chlorophenyl)-n-(4-pyridinylmethyl)-, 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
Drug Target(s) [2]:
KCNN2
NCIT ID [1]:
C98278

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.